TY - JOUR T1 - Molecular epidemiological characteristics of <em>Mycobacterium abscessus</em> complex in non-cystic fibrosis patients in Japan and Taiwan JF - medRxiv DO - 10.1101/2021.10.23.21265405 SP - 2021.10.23.21265405 AU - Mitsunori Yoshida AU - Jung-Yien Chien AU - Kozo Morimoto AU - Takeshi Kinjo AU - Akio Aono AU - Yoshiro Murase AU - Keiji Fujiwara AU - Yuta Morishige AU - Hiroaki Nagano AU - Ruwen Jou AU - Naoki Hasegawa AU - Manabu Ato AU - Yoshihiko Hoshino AU - Po-Ren Hsueh AU - Satoshi Mitarai Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/10/26/2021.10.23.21265405.abstract N2 - Mycobacterium abscessus complex (MABC) is an emerging non-tuberculous mycobacterium (NTM). Specific MABC clones are reportedly spreading globally in cystic fibrosis (CF) patients, however, associated genomic epidemiology studies are lacking in East Asia. Analysis of whole-genome sequencing data for MABC isolates from 220 pre-treatment, non-CF patients in Japan and Taiwan revealed that 112/220, 105/220, and 3/220 were M. abscessus subsp. abscessus (ABS), M. abscessus subsp. massiliense (MAS), and M. abscessus subsp. bolletii (BOL), respectively. No significant differences in subspecies composition were noted based on location. Moreover, &gt;50% of ABS and &gt;70% of MAS were related to four predominant clones in the region. Known mutations conferring acquired macrolide resistance were rare (1.4%) and not enriched in the predominant clones. Conversely, the macrolide-susceptible erm(41) T28C mutation was significantly enriched in one predominant ABS clone. The most predominant ABS clone was genetically related to the dominant circulating clone (DCC). Hence, we have clarified the relationship between the predominant clones in Japan and Taiwan, and those reported in the international CF patient community. Our results provide insights regarding the genetic characteristics of globally dominant and area-specific strains isolated from patients with or without CF, as well as differences between globally spread and regionally-specific strains.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by grants from the Japan Agency for Medical Research and Development (AMED) to SM (18fk0108043h0402 and 19fk0108043h0403), MA (20fk0108129 and 21fk0108139j0902), and YH (jp20fk0108043, jp20fk0108064, jp20fk0108075, jp20fk0108093, jp21fk0108129, jp21fk0108608, jp20jm0510004, jp20wm0125007, jp20wm0225004 and jp20wm0325003), grants-in-aid from the Japan Society for Fostering Joint International Research (B) to YH and MY (jp19KK0217), for Early-Career Scientists to MY (jp20K17205), and grants from Taiwan Ministry of Science and Technology for PRH (107-2314-B-002-211 and 108-2320-B-002-047) and JYC (107-2314-B-002-245). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was reviewed and approved by the Medical Research Ethics Committee of the Fukujuji Hospital (#18038), Keio University Hospital (#20080131), Okinawa Chubu Hospital (#2018-89), and National Taiwan University Hospital (#201808087RINA) for the use of human subjects.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the corresponding authors. ER -